公开(公告)号：WO1998022583A1

公开(公告)日：1998-05-28

申请号：PCT/US1997020951

申请日：1997-11-18

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  LI, Shengfeng ,  PHILLIPS, David, R.

IPC: C12N15/12

CPC classification number: C07K14/47 ,  A61K38/00

Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to beta 3 integrins, alpha IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.

Abstract translation: 本发明提供了结合β3整联蛋白，αIIb和Src激酶并参与整联蛋白介导的信号传导的蛋白质的氨基酸和核苷酸序列。 基于该公开内容，本发明提供了用于鉴定阻断整联蛋白介导的信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导调节生物和病理过程的试剂的方法以及阻断整合素介导的信号传导的试剂。

公开(公告)号：WO1997020045A2

公开(公告)日：1997-06-05

申请号：PCT/US1996018175

申请日：1996-11-08

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  CONLEY, Pamela, B. ,  JANTZEN, Hans-Michael

IPC: C12N15/12

CPC classification number: G01N33/5091 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5041 ,  G01N33/5044 ,  G01N33/5094 ,  G01N33/566 ,  G01N2500/10

Abstract: Novel purinergic receptors are provided, having research, diagnostic and therapeutic applications. Also provided are nucleic acids encoding these receptors, as well as expression systems for their production.

Abstract translation: 提供了新的嘌呤能受体，具有研究，诊断和治疗应用。 还提供了编码这些受体的核酸，以及用于其生产的表达系统。

公开(公告)号：WO1996040743A2

公开(公告)日：1996-12-19

申请号：PCT/US1996009285

申请日：1996-06-05

Applicant: COR THERAPEUTICS, INC. ,  MARLOWE, Charles, K. ,  SCARBOROUGH, Robert, M. ,  LAIBELMAN, Alan, M. ,  SINHA, Uma ,  ZHU, Bing-Yan

Inventor： COR THERAPEUTICS, INC.

IPC: C07K05/06

CPC classification number: C07K5/06095 ,  A61K38/00 ,  C07K5/06034 ,  C07K5/06086 ,  C07K5/06191

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 公开了与哺乳动物因子Xa具有活性的新型化合物，其盐和与其有关的组合物。 该化合物在体外或体内可用于预防或治疗凝血障碍。

公开(公告)号：WO9614843A3

公开(公告)日：1996-05-23

申请号：PCT/US9514723

申请日：1995-11-09

Applicant: COR THERAPEUTICS INC

Inventor： GIESE NEILL A ,  LOKKER NATHALIE ,  LAIBELMAN ALAN M ,  SCARBOROUGH ROBERT M

IPC: C07D231/38 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/455 ,  A61P43/00 ,  C07D231/40 ,  C07D401/06 ,  C07D405/04 ,  C07D409/06

CPC classification number: A61K31/455 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439

Abstract: A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of formula (I), wherein: R1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, polyaromatic, polyaromatic carbonyl, polyheteroaromatic or polyheteroaromatic carbonyl; R2 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, lower hydrocarboyl, 5- or 6-membered heterocyclic aromatic carbonyl, polyaromatic or polyheteroaromatic; R3 is H or lower alkyl; R5 is H, lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, halogen, or cyano; and R6 is H or lower hydrocarboyl. 00000

Abstract translation: 公开了选择性抑制激酶的方法，其包括将含有激酶的组合物与式（I）化合物接触，其中：R 1是低级烷基，低级烃基，芳基低级烷基，杂芳基低级烷基，5-或6- 多芳基，多芳基羰基，多杂芳基或多杂芳基羰基; R 2是低级烷基，低级烃基，芳基低级烷基，杂芳基低级烷基，5-或6-元杂环芳族，低级烃基，5-或6-元杂环芳族羰基，多芳族或多杂芳族; R3是H或低级烷基; R5是H，低级烷基，低级烃基，芳基低级烷基，杂芳基低级烷基，5-或6-元杂环芳族，卤素或氰基; R6为H或低级烃基。 00000

公开(公告)号：WO1993022335A1

公开(公告)日：1993-11-11

申请号：PCT/US1993003933

申请日：1993-04-27

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  SWIFT, Robert, L. ,  DU MEE, Charles, P. ,  RANDOLPH, Anne, E.

IPC: C07K01/00

CPC classification number: C07K14/75 ,  A61K9/0019 ,  A61K9/08 ,  A61K38/07 ,  A61K38/08 ,  A61K38/1703 ,  A61K38/36 ,  A61K38/39 ,  A61K47/12 ,  C07K14/78

Abstract: A (injectable biologically active) polypeptide is stabilized by dissolving said polypeptide forming a liquid solution in citrate buffer of about pH 5.0-5.5.

Abstract translation: 通过将形成液体溶液的所述多肽溶解在约pH5.5-5.5的柠檬酸盐缓冲液中来稳定A（可注射的生物活性）多肽。

公开(公告)号：WO1993011223A1

公开(公告)日：1993-06-10

申请号：PCT/US1992010430

申请日：1992-12-01

Applicant: COR THERAPEUTICS, INC. ,  WOLF, David ,  TOMLINSON, James, E.

Inventor： COR THERAPEUTICS, INC.

IPC: C12N01/21

CPC classification number: C07K14/71 ,  A61K38/00

Abstract: Cell lines and methods for high efficiency production of soluble peptides having platelet-derived growth factor (PDGF) ligand binding activity. Cell lines are provided which secrete soluble fragments from extracellular regions of PDGF receptor (PDGF-R) polypeptides. Methods using these cell lines for production of the fragments are also provided.

Abstract translation: 用于高效生产具有血小板衍生生长因子（PDGF）配体结合活性的可溶性肽的细胞系和方法。 提供从PDGF受体（PDGF-R）多肽细胞外区分泌可溶性片段的细胞系。 还提供了使用这些细胞系生产片段的方法。

公开(公告)号：WO2002070707A3

公开(公告)日：2002-09-12

申请号：PCT/US2001/049168

申请日：2001-12-18

Applicant: CURAGEN CORPORATION ,  COR THERAPEUTICS, INC. ,  PADIGARU, Muralidhara ,  GERLACH, Valerie, L. ,  SMITHSON, Glennda ,  STONE, David ,  BIN-YANG, Ruey ,  CONLEY, Pamela ,  HART, Matthew ,  TOMLINSON, James, E. ,  TOPPER, James, N. ,  KEKUDA, Ramesh ,  CASMAN, Stacie, J. ,  EDINGER, Schlomit ,  MACDOUGALL, John, R.

Inventor： PADIGARU, Muralidhara ,  GERLACH, Valerie, L. ,  SMITHSON, Glennda ,  STONE, David ,  BIN-YANG, Ruey ,  CONLEY, Pamela ,  HART, Matthew ,  TOMLINSON, James, E. ,  TOPPER, James, N. ,  KEKUDA, Ramesh ,  CASMAN, Stacie, J. ,  EDINGER, Schlomit ,  MACDOUGALL, John, R.

IPC: C12N15/12

Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

公开(公告)号：WO0216362A3

公开(公告)日：2002-06-13

申请号：PCT/US0141751

申请日：2001-08-17

Applicant: COR THERAPEUTICS INC ,  KYOWA HAKKO KOGYO KK ,  PANDEY ANJALI ,  SCARBOROUGH ROBERT M ,  MATSUNO KENJI ,  ICHIMURA MICHIO ,  NOMOTO YUJI ,  FUJIWARA SHIGEKI ,  IDE SHINICHI ,  TSUKUDA EIJI ,  IRIE JUNKO ,  ODA SHOJI

Inventor： PANDEY ANJALI ,  SCARBOROUGH ROBERT M ,  MATSUNO KENJI ,  ICHIMURA MICHIO ,  NOMOTO YUJI ,  FUJIWARA SHIGEKI ,  IDE SHINICHI ,  TSUKUDA EIJI ,  IRIE JUNKO ,  ODA SHOJI

IPC: A61P35/00 ,  C07D239/94 ,  C07D401/12 ,  C07D403/12 ,  A61K31/517

CPC classification number: C07D401/12 ,  C07D239/94 ,  C07D403/12

Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 本发明涉及对激酶的磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐，其抑制这些激酶的活性。 本发明还涉及抑制激酶并通过抑制激酶的磷酸化来治疗哺乳动物的疾病状态的方法。 本发明的一个特定方面提供了抑制PDGF受体的磷酸化以阻碍异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管性 重建，癌症和肾小球硬化。

公开(公告)号：WO0196398A3

公开(公告)日：2002-05-16

申请号：PCT/US0119230

申请日：2001-06-15

Applicant: COR THERAPEUTICS INC ,  HOMCY CHARLES J

Inventor： HOMCY CHARLES J

IPC: C07K14/705 ,  A01K67/027 ,  A61K35/00 ,  C12Q1/00

CPC classification number: C07K14/705 ,  A01K2217/05

Abstract: The present invention provides methods of identifying an agent effective for the treatment of heart failure by modulating the expression or activity of uncoupling proteins (UCP). The present invention also provides compositions and methods for treating heart failure.

Abstract translation: 本发明提供了通过调节解偶联蛋白（UCP）的表达或活性来鉴定有效治疗心力衰竭的药剂的方法。 本发明还提供了治疗心力衰竭的组合物和方法。

公开(公告)号：WO2002017711A3

公开(公告)日：2002-03-07

申请号：PCT/US2001/026936

申请日：2001-08-31

Applicant: COR THERAPEUTICS, INC. ,  RAMAKRISHNAN, Vanitha ,  PHILLIPS, David

Inventor： RAMAKRISHNAN, Vanitha ,  PHILLIPS, David

IPC: A01K67/027

Abstract: The present invention relates to therapeutics and diagnostics that take advantage of a novel signal transduction pathway in platelets. In addition, the present invention provides methods for identifying agents that modulate activities mediated by the novel transduction pathway including platelet activation and thrombosis.